Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5315MR)

This product GTTS-WQ5315MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Lymphoma, B cell research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5315MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3162MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ576MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ13393MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PR-1594804
GTTS-WQ2239MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aVWF81
GTTS-WQ2254MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ10153MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ2317MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ1811MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW